Category: covid-19

This study led by the UNC Institute for Global Health & Infectious Diseases, will enroll 7,500 COVID-positive individuals to answer some of the biggest questions about COVID-19. Investigators explain the study in this video. Over two years into the COVID-19 pandemic and researchers still are looking to answer some of...

  By Mina Hosseinipour, MD, MPH Officials announced the first confirmed case of COVID-19 in Malawi on April 2, 2020. At UNC Project Malawi, we’d been working for a month to carefully review and prepare for the virus. We established COVID preventive procedures and clinical management guidelines and planning for...

Projects include vaccinating farmworkers arriving in North Carolina, managing data from Nicaragua, and testing blood samples from Africa   UNC’s Office of Global Health Education (OGHE) is awarding $23,000 to teams of global health faculty and medical students to pursue COVID-19 related research and service learning in the spring or...

  Eli Lilly today released results of a clinical trial that found bamlanivimab, a monoclonal antibody, significantly reduced the risk of contracting COVID-19 among residents and staff of long-term care facilities. The Phase 3 trial was conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and...

A collaborative team, drawing in part on experience working with disease outbreaks in Africa, has remarkably transformed UNC’s Medical Intensive Care Unit to treat COVID-19 patients. They’ve demonstrated that it’s possible to provide critical care for patients while keeping providers safe. Like most of us during the pandemic, Billy Fischer,...

  A team of investigators from UNC’s Institute for Global Health and Infectious Diseases has been awarded $1.5 million from the National Institutes of Health to conduct a two-year implementation science study to scale up COVID-19 testing in North Carolina. The researchers will examine the impact of a COVID screening...

  Last week’s authorization by the U.S. Food and Drug Administration for emergency use of bamlanivimab feels like a shot in the arm, so to speak, for David Wohl, MD, a UNC infectious diseases physician and researcher. A monoclonal antibody developed by Eli Lilly to treat mild to moderate COVID-19,...

Human beings will continue to suffer from infectious diseases, some of them contagious. To fight a new disease, infectious disease physicians first work to determine the rules that govern the disease, its spread, and the gravity of the infection. Those rules then determine our prevention and treatment strategies, Institute Director...

Ernest Grant, RN, PhD, FAAN, president of American Nurses Association and an African American, shares why he is participating in COVID-19 vaccine trial   Spending a few hours at a University of North Carolina Health clinic, giving his health history and receiving an injection, might not be Ernest Grant’s favorite...

  The expanding COVID-19 pandemic has transformed the social lives of people across the world. A collaboration between researchers at the UNC Institute for Global Health & Infectious Disease, the London School of Hygiene and Tropical Medicine, and the Academic Network for Sexual and Reproductive Health and Rights Policy is...

On the heels of FDA authorization of convalescent plasma as a treatment for COVID-19, UNC researchers are conducting a clinical trial to determine the safety and efficacy of plasma that includes a higher amount of neutralizing antibodies against SARS-CoV-2. The new Coronavirus-inactivating Plasma (CoVIP) research clinical trial is designed to...

  UNC Institute for Global Health and Infectious Diseases researchers have begun phase 2 and phase 3 evaluations of promising treatments for COVID-19. The UNC School of Medicine joins more than 25 initial sites participating in the clinical trials through ACTIV-2, a public-private partnership sponsored by the NIH’s National Institute...